← Human Trials & Peer-Reviewed Studies
No difference in intestinal strontium absorption after oral or IV calcitriol in children with secondary hyperparathyroidism. The European Study Group on Vitamin D in Children with Renal Failure.
Plain-language guide to PMID 10972662 (2000): randomized and crossover controlled clinical trial of Vitamin D, K2, Magnesium and Zinc, hyperparathyroidism.
Key Facts
- PMID
- 10972662
- Journal
- Kidney international
- Year
- 2000
- Study type
- Controlled Clinical Trial
- Authors
- Ardissino G et al. (6 authors)
- DOI
- 10.1046/j.1523-1755.2000.00255.x
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Vitamin D, K2, Magnesium and Zinc in the context of hyperparathyroidism, published as a controlled clinical trial.
Oral and intravenous calcitriol bolus therapy are both recommended for the treatment of secondary hyperparathyroidism, but it has been claimed that the latter is less likely to induce absorptive hypercalcemia.
Who Took Part
The age groups tagged for this paper are young children, children and teenagers, both men and women.
Baseline control values for Sr absorption were obtained in a separate group of children with CRF of similar severity.
How the Study Was Run
The design is described as randomized and crossover.
Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
In the crossover set-up each of the participants took both Vitamin D, K2, Magnesium and Zinc and the comparison in turn, acting as their own control.
What Was Measured
Oral and intravenous calcitriol bolus therapy are both recommended for the treatment of secondary hyperparathyroidism, but it has been claimed that the latter is less likely to induce absorptive hypercalcemia.
The subject headings attached to it are Calcitriol, Calcium, Calcium Channel Agonists, Creatinine, Hypercalcemia, Hyperparathyroidism, Secondary and Intestinal Absorption.
What This Means in Plain Language
The paper is a randomized and crossover study of Vitamin D, K2, Magnesium and Zinc in people with hyperparathyroidism.
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2000 (Kidney international), a journal based in United States.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, Hyperparathyroidism research.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.